<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2016.61008</article-id><article-id pub-id-type="publisher-id">MD-17268</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20160100000_33955774.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  妇科癌症患者化疗后与认知功能障碍相关的研究
  A Study of Chemotherapy-Related Cognitive Impairment in Gynecologic Cancer Patients
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>志辽</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>睿</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>小兰</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>玉珠</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>必近</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>钟</surname><given-names>沅月</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>荣辉</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>中山大学孙逸仙纪念医院妇产科，广东 广州</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>chen.zhl@163.com(陈志)</email>;<email>1176362624@qq.com(张睿)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>03</month><year>2016</year></pub-date><volume>06</volume><issue>01</issue><fpage>40</fpage><lpage>46</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：1) 分析妇科癌症患者化疗后的认知功能状态。2) 分析化疗后认知功能障碍差异程度的相关因素。方法：2009年至2011年，妇科病房53名妇科癌症患者(Group A)入选本研究，年龄为18岁至66岁，其中患宫颈癌22例，卵巢癌24例，及其他妇科癌症7例。其中接受TP方案辅助化疗47例，接受其他方案化疗6例。化疗病人分组,根据他们的年龄(pre-perimenopausal &lt;45岁和post-perimenopausal期 ≥45岁)，教育水平(低教育不到9年的教育和高等教育超过9年的教育)，类型的癌症(宫颈癌、卵巢癌、其他癌症)，类型的化疗方案(TP方案,其他方案)。对照组分为两组，非化学疗法的患者(B组)和健康对照组(C组)。根据患者的化疗情况分成5个研究组，对照组分为2组。采用2个主观问卷调查(Everyday Memory Questionnaires及CAMDEX)和1个客观问题测试(Random Number Test)，根据问题答案对错计分，判断受试对象的认知功能受损情况。问题测试在患者未接受任何治疗前(T1)和患者接受两次或者以上化疗疗程后3~4周后(T2)进行测试。患者的测试结果与对照组进行比较。结果：1) 资料显示化疗患者比非化疗患者和健康对照组出现更多的认知问题。2) 在化疗前后自身对照研究中发现，化疗后认知功能障碍与化疗前的有统计学差异(p = 0.039)。3) 妇科癌症患者化疗后认知功能障碍，在围绝经前组和围绝经后组间，有统计学差异(p = 0.031)。4) 妇科癌症患者化疗后认知功能障碍，在文化程度高组和文化程度低组间，有统计学差异(p = 0.010)。5) 妇科癌症患者化疗后认知功能障碍，在宫颈癌组和卵巢癌组间，没有统计学差异(p = 0.304)。结论：1) 妇科癌症患者化疗后认知功能障碍与健康人组、非化疗病人组有统计学差异。2) 在化疗前后自身对照研究中发现，化疗后患者认知功能障碍与化疗前的有统计学差异。3) 妇科癌症患者化疗后认知功能障碍，在围绝经前组和围绝经后组间有统计学差异。4) 妇科癌症患者化疗后认知功能障碍，在文化程度高组和文化程度低组间有统计学差异。5) 妇科癌症患者TP方案化疗后认知功能障碍，在宫颈癌组和卵巢癌组间没有统计学差异。
   Objectives: 1) To evaluate post-chemotherapy cognitive functions in gynecology oncology patients; 2) To analyze the factors that influence memory impairment in those patients. Methods: The expe-rimental group (Group A) consisted of 53 patients admitted between year 2009-2011, with age ranging from 18 - 66 years old, suffering from cervical cancer (n = 22), ovarian cancer (n = 24), and other gynecologic cancer types grouped together (n = 7), treated with adjuvant TP regimen chemotherapy (n = 47) or other regimen chemotherapy grouped together (n = 6). The chemothe-rapy patients are grouped according to their age (pre-perimenopausal &lt;45 years old and post-pe- rimenopausal period ≥45 years old), education level (lower educated of less than 9 years of edu-cation and higher educated of more than 9 years of education), types of cancer (cervical cancer, ovarian cancer, other cancer), types of chemotherapy regimen received (TP regimen, other regi-men). The control group is divided into 2 groups, non-chemotherapy patients (Group B) and heal- thy controls (Group C). According to patients’ chemotherapy is divided into five group, control group is divided into 2 groups. Using two subjective questionnaires (Everyday Memory Questionnaires and CAMDEX) and 1 objective problems Test (Random Number Test), right and wrong points according to the problem, determine subjects of cognitive function damage. Problems before test in patients who did not receive any treatment (T1) and patients received two or more than 3 to 4 weeks after chemotherapy regimen (T2) after the test. The patient test results comparing with control group. Results: 1) The data show that chemotherapy patients have more cognitive problems than chemotherapy patients and healthy controls. 2) Found in its own control study before and after chemotherapy, the cognitive dysfunction after chemotherapy and before chemotherapy is statistically significant (p = 0.039). 3) Gynecological cancer after chemotherapy in patients with cognitive dysfunction, and in the scarf premenopausal and postmenopausal group, has statistical difference (p = 0.031). 4) Gynecological cancer after chemotherapy in patients with cognitive dys-function, and in the cultural level between high and low degree of cultural groups, is statistically significant (p = 0.010). 5) Gynecological cancer after chemotherapy in patients with cognitive dys-function, between cervical cancer and ovarian cancer group, has no statistical difference (p = 0.304). Conclusions: 1) There was a statistically significant difference of cognitive impairment prevalence between chemotherapy patients and non-chemotherapy control groups. 2) Among chemotherapy patients participated in baseline cognitive assessment, there was a statistically significant difference in cognitive impairment prevalence between pre- and post-chemotherapy assessment. 3) Among chemotherapy patients, there was a statistically significant difference in cognitive impairment prevalence between pre-perimenopausal patients and post-perimenopausal patients. 4) Among chemotherapy patients, there was a statistically significant difference in cognitive impairment prevalence between lower educated patients and higher educated patients. 5) Among TP regimen chemotherapy patients, there was no statistically significant difference in cognitive impairment prevalence between ovarian cancer patients and cervical cancer patients.
 
</p></abstract><kwd-group><kwd>妇科癌症，化疗，认知功能障碍，化疗脑, Gynecologic Cancer</kwd><kwd> Chemotherapy</kwd><kwd> Cognitive Impairment</kwd><kwd> Chemobrain</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>妇科癌症患者化疗后与认知功能障碍 相关的研究<sup> </sup></title><p>陈志辽，张睿<sup>*</sup>，张小兰，李玉珠，陈必近，钟沅月，周荣辉</p><p>中山大学孙逸仙纪念医院妇产科，广东 广州</p><disp-formula id="hanspub.17268-formula621"><graphic xlink:href="http://html.hanspub.org/file/8-2170099x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年3月10日；录用日期：2016年3月27日；发布日期：2016年3月30日</p><disp-formula id="hanspub.17268-formula622"><graphic xlink:href="http://html.hanspub.org/file/8-2170099x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：1) 分析妇科癌症患者化疗后的认知功能状态。2) 分析化疗后认知功能障碍差异程度的相关因素。方法：2009年至2011年，妇科病房53名妇科癌症患者(Group A)入选本研究，年龄为18岁至66岁，其中患宫颈癌22例，卵巢癌24例，及其他妇科癌症7例。其中接受TP方案辅助化疗47例，接受其他方案化疗6例。化疗病人分组,根据他们的年龄(pre-perimenopausal &lt;45岁和post-perimenopausal期 ≥45岁)，教育水平(低教育不到9年的教育和高等教育超过9年的教育)，类型的癌症(宫颈癌、卵巢癌、其他癌症)，类型的化疗方案(TP方案,其他方案)。对照组分为两组，非化学疗法的患者(B组)和健康对照组(C组)。根据患者的化疗情况分成5个研究组，对照组分为2组。采用2个主观问卷调查(Everyday Memory Questionnaires及CAMDEX)和1个客观问题测试(Random Number Test)，根据问题答案对错计分，判断受试对象的认知功能受损情况。问题测试在患者未接受任何治疗前(T1)和患者接受两次或者以上化疗疗程后3~4周后(T2)进行测试。患者的测试结果与对照组进行比较。结果：1) 资料显示化疗患者比非化疗患者和健康对照组出现更多的认知问题。2) 在化疗前后自身对照研究中发现，化疗后认知功能障碍与化疗前的有统计学差异(p = 0.039)。3) 妇科癌症患者化疗后认知功能障碍，在围绝经前组和围绝经后组间，有统计学差异(p = 0.031)。4) 妇科癌症患者化疗后认知功能障碍，在文化程度高组和文化程度低组间，有统计学差异(p = 0.010)。5) 妇科癌症患者化疗后认知功能障碍，在宫颈癌组和卵巢癌组间，没有统计学差异(p = 0.304)。结论：1) 妇科癌症患者化疗后认知功能障碍与健康人组、非化疗病人组有统计学差异。2) 在化疗前后自身对照研究中发现，化疗后患者认知功能障碍与化疗前的有统计学差异。3) 妇科癌症患者化疗后认知功能障碍，在围绝经前组和围绝经后组间有统计学差异。4) 妇科癌症患者化疗后认知功能障碍，在文化程度高组和文化程度低组间有统计学差异。5) 妇科癌症患者TP方案化疗后认知功能障碍，在宫颈癌组和卵巢癌组间没有统计学差异。</p><p>关键词 :妇科癌症，化疗，认知功能障碍，化疗脑</p><disp-formula id="hanspub.17268-formula623"><graphic xlink:href="http://html.hanspub.org/file/8-2170099x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>癌症患者化疗后生存率一直在稳步提高，妇科肿瘤患者也不例外。预计到2020年，全球将有7000万癌症幸存者。随癌症存活生存率不断的上升，医生正面临着新的问题——如何研究和治疗化疗引起的副作用 [<xref ref-type="bibr" rid="hanspub.17268-ref1">1</xref>] - [<xref ref-type="bibr" rid="hanspub.17268-ref3">3</xref>] 。有些化疗引起的副作用已经了解，如免疫抑制，骨髓抑制，胃肠道不适，不孕，脱发等，但对化疗引起认功能知障碍的机制认识不多 [<xref ref-type="bibr" rid="hanspub.17268-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.17268-ref4">4</xref>] 。如果一个肿瘤患者，化疗后成了一个痴呆病人，实为医疗的悲剧。为了避免化疗后严重认知功能障碍的发生，研究这种副作用出现的规律，以及制定临床治疗方法显得非常迫切了。</p><p>在1974年，“化疗引起认知功能障碍”的现象首次被发现，但直到20世纪90年代末，医生和研究人员才确定化疗与认知功能障碍上的联系。这种认知功能障碍往往出现在化疗后，也称为“化疗脑chemobrain”，这种副反应包括记忆力减退、注意力不集中、思考迟钝、以及其他微少认知缺陷的症状 [<xref ref-type="bibr" rid="hanspub.17268-ref5">5</xref>] - [<xref ref-type="bibr" rid="hanspub.17268-ref8">8</xref>] 。化疗作为辅助治疗，使癌症患者生存率的上升，导致化疗后认知功能障碍的病例明显增加。在这种情况下，即使是认知功能损害轻微，但患者持续的认知障碍会对患者以及家庭成员的生活质量带来相当大的负面影响。这种问题对于那些拥有专业和社会地位的病人来说，更具危害性。因为注意力的缺乏或记忆丧失，严重影响他们从事日常工作和担负社会责任 [<xref ref-type="bibr" rid="hanspub.17268-ref9">9</xref>] - [<xref ref-type="bibr" rid="hanspub.17268-ref12">12</xref>] 。另一方面，这些损害影响了化疗病人选择相应治疗的判断力，例如：病人执意拒绝好的治疗方案，却偏执地尝试有害的治疗方案，造成治疗上的恶性循环，使病情越来越严重，终有一日病入膏肓 [<xref ref-type="bibr" rid="hanspub.17268-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.17268-ref14">14</xref>] 。</p><p>为了增加对化疗与认知功能障碍之间关系的了解，本研究分析妇科癌症病人化疗后，认知功能的改变，以及这种改变与各种因素的关系，了解妇科癌症患者化疗脑发生的规律。使医务人员能更精确地拟定早期诊断该病的标准、及作出的治疗决策、在化疗和生活质量二者之间得到更好的权衡。</p></sec><sec id="s4"><title>2. 研究目的</title><p>分析妇科癌症患者化疗后的认知功能状态；分析化疗后认知功能障碍差异程度的相关因素。</p></sec><sec id="s5"><title>3. 资料和方法</title><p>2009年至2014年，妇科病房63名妇科癌症患者(Group A)入选本研究，年龄为18岁至66岁，其中患宫颈癌41例，卵巢癌22例，及其他妇科癌症7例。其中接受TP方案辅助化疗57例，接受其他方案化疗6例。</p><p>根据患者的化疗情况；年龄(围绝经前45岁以下，围绝经后45岁以上)；文化程度(无高等教育——高中以下；高等教育——高中以上)；癌症类型(宫颈癌，卵巢癌和其他妇科癌症)；化疗方案类型(TP方案，非TP方案)分成5个研究组。对照组分为2组，非化疗患者对照组(Group B)和健康对照组(Group C)。A和B组无既往癌症或其他重大疾病史，未接受激素治疗和脑部放射治疗史。C组无任何重大疾病史。其他入选标准为：年龄18至70岁，至少有6年的正规教育。患神经或精神疾病者，使用精神药物者，有吸毒或酗酒的历史是从收集研究数据之前排除。</p><p>采用2个主观问卷调查(Everyday Memory Questionnaires及CAMDEX，见附录)和1个客观问题测试(Random Number Test)，根据问题答案对错计分，判断受试对象的认知功能受损情况。问题测试在患者未接受任何治疗前(T1)和患者接受两次或者以上化疗疗程后3~4周后(T2)进行测试。患者的测试结果与对照组进行比较 [<xref ref-type="bibr" rid="hanspub.17268-ref15">15</xref>] - [<xref ref-type="bibr" rid="hanspub.17268-ref17">17</xref>] 。</p></sec><sec id="s6"><title>4. 讨论</title><p>1) 资料显示化疗患者比非化疗患者和健康对照组出现更多的认知问题，主要存在于记忆的活动，追溯和空间记忆这些方面 [<xref ref-type="bibr" rid="hanspub.17268-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.17268-ref19">19</xref>] 。在需要有注意力、集中力和工作记忆的正常运行的客观测试中，化疗患者的水平明显低于对照组。主观主诉和客观的测试之间相关。在至少2个测试使用SD = 1.5作为切断点，或在至少1个测试中使用SD = 2作为切断点，结果显示在26.42%接受化疗治疗的患者表现出认知功能障碍，而非化疗患者仅有8.00%和健康对照组仅有5.45%表现出认知功能障碍 [<xref ref-type="bibr" rid="hanspub.17268-ref20">20</xref>] 。</p><p>2) 在化疗前后自身对照研究中发现，有33.33%接受化疗后的患者表现出认知功能障碍，而化疗前的患者并未表现出认知功能障碍。化疗后认知功能障碍与化疗前的有统计学差异 (p = 0.039)。</p><p>3) 妇科癌症患者化疗后认知功能障碍，有37.93%围绝经后患者表现出认知功能障碍，而围绝经前患者仅有12.50%表现出认知功能障碍。在围绝经前组和围绝经后组间，有统计学差异(p = 0.031)。</p><p>4) 妇科癌症患者化疗后认知功能障碍，有42.31%无高等教育患者表现出认知功能障碍，而高等教育患者仅有11.11%表现出认知功能障碍。在文化程度高组和文化程度低组间，有统计学差异(p = 0.010)。</p><p>5) 妇科癌症患者化疗后认知功能障碍，有33.33%卵巢癌患者表现出认知功能障碍，19.05%宫颈癌患者有表现出认知功能障碍。在宫颈癌组和卵巢癌组间，没有统计学差异(p = 0.304)。</p></sec><sec id="s7"><title>5. 结论</title><p>1) 妇科癌症患者化疗后认知功能障碍与健康人组、非化疗病人组有统计学差异。</p><p>2) 在化疗前后自身对照研究中发现，化疗后患者认知功能障碍与化疗前的有统计学差异。</p><p>3) 妇科癌症患者化疗后认知功能障碍，在围绝经前组和围绝经后组间有统计学差异。</p><p>4) 妇科癌症患者化疗后认知功能障碍，在文化程度高组和文化程度低组间有统计学差异。</p><p>5) 妇科癌症患者TP方案化疗后认知功能障碍，在宫颈癌组和卵巢癌组间没有统计学差异。</p></sec><sec id="s8"><title>文章引用</title><p>陈志辽,张睿,张小兰,李玉珠,陈必近,钟沅月,周荣辉. 妇科癌症患者化疗后与认知功能障碍相关的研究 A Study of Chemotherapy-Related Cognitive Impairment in Gynecologic Cancer Patients[J]. 医学诊断, 2016, 06(01): 40-46. http://dx.doi.org/10.12677/MD.2016.61008</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.17268-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Minisini, A., Atalay, G. et al. (2004) What Is the Effect of Systemic Anticancer Treatment on Cognitive Function? Lancet Oncology, 5, 273-282. &lt;br&gt;http://dx.doi.org/10.1016/S1470-2045(04)01465-2</mixed-citation></ref><ref id="hanspub.17268-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Luo, L. and Craik, F.I. (2008) Aging and Memory: A Cognitive Approach. Canadian Journal of Psychiatry, 53, 346- 353.</mixed-citation></ref><ref id="hanspub.17268-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hannon, B. and Daneman, M. (2009) Age-Related Changes in Reading Comprehension: An Individual-Differences Perspective. Experimental Aging Research, 35, 432-456. &lt;br&gt;http://dx.doi.org/10.1080/03610730903175808</mixed-citation></ref><ref id="hanspub.17268-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">(2010) Hyperin-tensities. Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition, 19, 1-17.</mixed-citation></ref><ref id="hanspub.17268-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ahles, T.A., Saykin, A.J., et al. (2002) Neuropsychologic Impact of Standard-Dose Systemic Chemothe-rapy in Long- Term Survivors of Breast Cancer and Lymphoma. Journal of Clinical Oncology, 485-493.  
&lt;br&gt;http://dx.doi.org/10.1200/JCO.20.2.485</mixed-citation></ref><ref id="hanspub.17268-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Poppelreuter, R.C., Mannes, A.J., Clark, U.S. and Bennett, G.J. (2004) Cognitive Dysfunction and Subjective Complaints of Cancer Patients: A Cross-Sectional Study in a Cancer Rehabilitation Centre. European Journal of Cancer, 40, 43-49. &lt;br&gt;http://dx.doi.org/10.1016/j.ejca.2003.08.001</mixed-citation></ref><ref id="hanspub.17268-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Cimprich, B., So, H. et al. (2005) Pre-Treatment Factors Re-lated to Cognitive Functioning in Women Newly Diagnosed with Breast Cancer. Psychooncology, 14, 70-78. &lt;br&gt;http://dx.doi.org/10.1002/pon.821</mixed-citation></ref><ref id="hanspub.17268-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Tangpong, J., Cole, M.P., Sultana, R., et al. (2007) Adriamycin-Mediated Nitration of Manganese Superoxide Dismutase in the Central Nervous System: Insight into the Mechanism of Chemobrain. Journal of Neurochemistry, 100, 191- 201. &lt;br&gt;http://dx.doi.org/10.1111/j.1471-4159.2006.04179.x</mixed-citation></ref><ref id="hanspub.17268-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Weiss, B. (2008) Chemobrain: A Translational Chal-lenge for Neurotoxicology. Neurotoxicology, 29, 891-898.  
&lt;br&gt;http://dx.doi.org/10.1016/j.neuro.2008.03.009</mixed-citation></ref><ref id="hanspub.17268-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Konat, G.W., Kraszpulski, M., James, I., Zhang, H.T. and Abraham, J. (2008) Cognitive Dysfunction Induced by Chronic Administration of Common Cancer Chemotherapeu-tics in Rats. Metabolic Brain Disease, 23, 325-333.  
&lt;br&gt;http://dx.doi.org/10.1007/s11011-008-9100-y</mixed-citation></ref><ref id="hanspub.17268-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Dietrich, J., Han, R.L., Yang, Y., Mayer-Prösche, M. and Noble, M. (2006) CNS Progenitor Cells and Oligodendrocytes Are Targets of Chemotherapeutic Agents in Vitro and in Vivo. Journal of Biology, 5, 22.  
&lt;br&gt;http://dx.doi.org/10.1186/jbiol50</mixed-citation></ref><ref id="hanspub.17268-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Han, R.L., Yang, Y.M., Dietrich, J., Luebke, A., Mayer-Pröschel, M. and Noble, M. (2008) Systemic 5-Fluorouracil Treatment Causes a Syndrome of Delayed Myelin Destruction in the Central Nervous System. Journal of Biology, 7, 12. &lt;br&gt;http://dx.doi.org/10.1186/jbiol69</mixed-citation></ref><ref id="hanspub.17268-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Tannock, I., Winocur, G., et al. (2006) The Effects of the Anti-Cancer Drugs, MTX and 5-FU on Cognitive Function in Mice. Pharmacology Bi-ochemistry and Behavior, 85, 66-75. &lt;br&gt;http://dx.doi.org/10.1016/j.pbb.2006.07.010</mixed-citation></ref><ref id="hanspub.17268-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Inagaki, M., Yoshikawa, E., Matsuoka, Y., et al. (2007) Smaller Regional Volumes of Brain Gray and White Matter Demonstrated in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy. Cancer, 109, 146-156.  
&lt;br&gt;http://dx.doi.org/10.1002/cncr.22368</mixed-citation></ref><ref id="hanspub.17268-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Silverman, D.H., Dy, C.J., Castellon, S.A., et al. (2007) Altered Fron-tocortical, Cerebellar, and Basal Ganglia Activity in Adjuvant-Treated Breast Cancer Survivors 5-10 Years after Chemotherapy. Breast Cancer Research and Treatment, 103, 303-311. &lt;br&gt;http://dx.doi.org/10.1007/s10549-006-9380-z</mixed-citation></ref><ref id="hanspub.17268-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Mock, V., Atkinson, A., et al. (2000) NCCN Practice Guide-lines for Cancer-Related Fatigue. Oncology (Huntingt), 14, 115-161.</mixed-citation></ref><ref id="hanspub.17268-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Jenkins, V., Shilling, V., et al. (2006) A 3-Year Prospective Study of the Effects of Adjuvant Treatments on Cognition in Women with Early Stage Breast Cancer. British Journal of Cancer, 94, 828-834.  
&lt;br&gt;http://dx.doi.org/10.1038/sj.bjc.6603029</mixed-citation></ref><ref id="hanspub.17268-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hermelink, K. (2007) Cognitive Function during Neoadjuvant Chemotherapy for Breast Cancer: Results of a Prospective, Multicenter, Longitudinal Study. Cancer, 109, 1905-1913.</mixed-citation></ref><ref id="hanspub.17268-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bender, C.M., Sereika, S.M., et al. (2006) Cognitive Impairment Associated with Adjuvant Therapy in Breast Cancer. Psycho-Oncology, 15, 422-430. &lt;br&gt;http://dx.doi.org/10.1002/pon.964</mixed-citation></ref><ref id="hanspub.17268-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wefel, J.S., Lenzi, R., et al. (2004) Chemobrain in Breast Carcinoma? A Prologue. Cancer, 101, 46.  
&lt;br&gt;http://dx.doi.org/10.1002/cncr.20393</mixed-citation></ref></ref-list></back></article>